ID   VCaP-R
AC   CVCL_C0QQ
DR   cancercelllines; CVCL_C0QQ
DR   Wikidata; Q112930541
RX   PubMed=30244336;
CC   Population: Caucasian.
CC   Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line).
CC   Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol).
CC   Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 11876; TMPRSS2; Name(s)=TMPRSS2-ERG (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Ile219Val (c.655A>G); ClinVar=VCV000036557; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Bone, vertebra; UBERON=UBERON_0002412.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2235 ! VCaP
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 23-06-22; Last updated: 05-10-23; Version: 6
//
RX   PubMed=30244336; DOI=10.1007/s00345-018-2501-6;
RA   Samli H., Samli M., Vatansever B., Ardicli S., Aztopal N., Dincel D.,
RA   Sahin A., Balci F.;
RT   "Paclitaxel resistance and the role of miRNAs in prostate cancer cell
RT   lines.";
RL   World J. Urol. 37:1117-1126(2019).
//